Lv71
3250 积分 2021-10-14 加入
胶质瘤分子病理诊断中国专家共识（2025版）
56分钟前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
7天前
已完结
The Value of Multidisciplinary Neuro-oncological Tumor Boards to Increase the Accuracy of FET PET for Identifying Brain Tumor Relapse
7天前
已完结
Quantifying the utility of a multidisciplinary neuro-oncology tumor board
7天前
已完结
Exploring the impact of primary care utilization and health information exchange upon treatment patterns and clinical outcomes of glioblastoma patients
14天前
已完结
Divided care, diminished outcomes? The impact of care fragmentation on survival in glioblastoma
14天前
已完结
Divided care, diminished outcomes? The impact of care fragmentation on survival in glioblastoma
14天前
已完结
多学科MDT诊疗模式在胶质母细胞瘤患者诊疗中的应用价值
14天前
已关闭
Glioblastoma: Overcoming fundamental biological and delivery barriers to therapy
14天前
已完结
European Cancer Organisation Essential Requirements for Quality Cancer Care: Adult glioma
23天前
已完结
皖公网安备34019202002308
